CHATSWORTH, Calif., May 27, 2009 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, has elected Dr. Beth Y. Karlan to its Board of Directors, it was announced today by Cesar M. Garcia, Chairman, President and Chief Executive Officer. “The addition to our Board of such a distinguished cancer scientist and physician as Dr. Karlan underscores our commitment not only to our core business but to our belief in the importance of our NADiA(r) (nucleic acid detection immunoassay) technology platform with applications in early detection of relapse in prostate cancer, AIDS and other diseases,” said Mr. Garcia. “Dr. Karlan’s expertise in early detection of cancer, genetics and biomarkers which form a molecular signature that predicts response to therapy and survival, makes her an ideal corporate Director for Iris as we advance in our research, development and commercialization of our molecular diagnostics and advanced hematology platforms. She brings unique skills and an impressive record of clinical and educational contributions to the advancement of cancer treatment and detection.”
